Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nitric Oxide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 8Inomax

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 574

    2019 Revenue in Millions : 571

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2021 Revenue in Millions : 449

    2020 Revenue in Millions : 574

    Growth (%) : -22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Diseases

    Currency : USD

    2022 Revenue in Millions : 340

    2021 Revenue in Millions : 449

    Growth (%) : -24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Diseases

    Currency : USD

    2023 Revenue in Millions : 303

    2022 Revenue in Millions : 340

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2016 Revenue in Millions : 474

    2015 Revenue in Millions : 185

    Growth (%) : 156

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2017 Revenue in Millions : 505

    2016 Revenue in Millions : 593

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2018 Revenue in Millions : 543

    2017 Revenue in Millions : 505

    Growth (%) : 8%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Inomax

    Nitric Oxide

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Inomax

    Ireland
    arrow
    Fi Europe 2024
    Not Confirmed

    Mallinckrodt Plc

    Nitric Oxide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2019 Revenue in Millions : 571

    2018 Revenue in Millions : 543

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF